Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.63 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034699 | 0.82 | RAB9A (0.78) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1034601 | 0.82 | MAPT (0.50) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1033294 | 0.81 | TP53 (0.69) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1034707 | 0.80 | LMNA (0.85) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1034482 | 0.80 | MAPT (0.76) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1035549 | 0.78 | TP53 (0.76) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1031213 | 0.77 | HSD17B10 (0.73) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1034430 | 0.77 | HSD17B10 (0.73) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1036246 | 0.77 | TP53 (0.68) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1034520 | 0.77 | MAPT (0.62) | MAPTHSD17B10HPGDKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080569-B2 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-12-20 | — | — | US | claimed |
| EP-2086537-B1 | IMIDAZO[2,1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-01-26 | — | — | EP | claimed |
| US-20100004299-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-01-07 | — | — | US | claimed |
| EP-2086537-A1 | IMIDAZO[2, 1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-08-12 | — | — | EP | claimed |
| WO-2008058641-A1 | IMIDAZO[2, 1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-05-22 | — | — | WO | claimed |
| EP-1923062-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | claimed |
| US-8080569-B2 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-12-20 | — | — | US | disclosed |
| US-8080569-B2 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-12-20 | — | — | US | disclosed |
| US-8080569-B2 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-12-20 | — | — | US | disclosed |
| EP-2086537-B1 | IMIDAZO[2,1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-01-26 | — | — | EP | disclosed |
| EP-2086537-B1 | IMIDAZO[2,1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-01-26 | — | — | EP | disclosed |
| US-20100004299-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004299-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004299-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2086537-A1 | IMIDAZO[2, 1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008058641-A1 | IMIDAZO[2, 1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058641-A1 | IMIDAZO[2, 1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-05-22 | — | — | WO | disclosed |
| EP-1923062-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004299-A1 | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals | NOS1, NOS2, NOS3 | MAPT 4688/4885HSD17B10 736/4885HPGD 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.